{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T19:06:56Z","timestamp":1788721616535,"version":"build-2803163510"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.addr.2022.114252","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:46:57Z","timestamp":1648604817000},"page":"114252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Delivering macrolide antibiotics to heal a broken heart \u2013 And other inflammatory conditions"],"prefix":"10.1016","volume":"184","author":[{"given":"Vincent J.","family":"Venditto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0005","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1124\/pharmrev.121.000300","article-title":"Nonantimicrobial actions of macrolides: overview and perspectives for future development","volume":"73","author":"Kricker","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0010","first-page":"281","article-title":"Ilotycin, a new antibiotic","volume":"2","author":"McGuire","year":"1952","journal-title":"Antibiot. Chemother. (Northfield)"},{"key":"10.1016\/j.addr.2022.114252_b0015","unstructured":"Center for Disease Control and Prevention, Outpatient antibiotic prescriptions - United States, 2020."},{"key":"10.1016\/j.addr.2022.114252_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.574425","article-title":"Immunomodulatory effects of azithromycin revisited: potential applications to COVID-19","volume":"12","author":"Venditto","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3949\/ccjm.80a.13077","article-title":"Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused?","volume":"80","author":"Giudicessi","year":"2013","journal-title":"Clev. Clin. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0030","doi-asserted-by":"crossref","first-page":"16596","DOI":"10.1038\/s41598-020-73593-0","article-title":"Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction","volume":"10","author":"Al-Darraji","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114252_b0035","doi-asserted-by":"crossref","unstructured":"H. Brockmann, W H. Pikromycin, ein bitter schmeckendes antibioticum aus actinomyeceten. Chem. Ber. 84 (1951) 284\u2013288.","DOI":"10.1002\/cber.19510840306"},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1248\/yakushi1947.112.9_593","article-title":"Research and development of clarithromycin","volume":"112","author":"Omura","year":"1992","journal-title":"Yakugaku Zasshi"},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0045","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.31.12.1948","article-title":"Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution","volume":"31","author":"Girard","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0050","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"Retsema","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7164\/antibiotics.39.660","article-title":"Antibacterial activity of roxithromycin: a laboratory evaluation","volume":"39","author":"Chantot","year":"1986","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrmicro3155","article-title":"Ribosome-targeting antibiotics and mechanisms of bacterial resistance","volume":"12","author":"Wilson","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"issue":"18","key":"10.1016\/j.addr.2022.114252_b0065","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bph.13936","article-title":"The macrolide antibiotic renaissance","volume":"174","author":"Dinos","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1469-0691.2000.00185.x","article-title":"Ketolides-telithromycin, an example of a new class of antibacterial agents","volume":"6","author":"Bryskier","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.addr.2022.114252_b0075","doi-asserted-by":"crossref","unstructured":"K.D. Clay, J.S. Hanson, S.D. Pope, R.W. Rissmiller, P.P. Purdum, 3rd, P.M. Banks, Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review, Ann. Int. Med. 144 (6) (2006) 415\u2013420.","DOI":"10.7326\/0003-4819-144-6-200503210-00121"},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/cid\/cis847","article-title":"Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America","volume":"55","author":"Shulman","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0085","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1542\/peds.2012-3488","article-title":"The diagnosis and management of acute otitis media","volume":"131","author":"Lieberthal","year":"2013","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0090","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.addr.2022.114252_b0095","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14656566.1.3.507","article-title":"Clarithromycin for Helicobacter pylori infection","volume":"1","author":"Leung","year":"2000","journal-title":"Expert Opin. Pharmacother."},{"issue":"18","key":"10.1016\/j.addr.2022.114252_b0105","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.3748\/wjg.v20.i18.5283","article-title":"Treatment of Helicobacter pylori infection: current status and future concepts","volume":"20","author":"Yang","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually Transmitted Infections Treatment Guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm. Rep."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0120","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/embo-reports\/kve062","article-title":"Structural basis for selectivity and toxicity of ribosomal antibiotics","volume":"2","author":"B\u00f6ttger","year":"2001","journal-title":"EMBO Rep."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0125","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/AAC.33.9.1413","article-title":"New directions for macrolide antibiotics: structural modifications and in vitro activity","volume":"33","author":"Kirst","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/39.5.669","article-title":"In-vitro activity of ketolides against mycoplasmas","volume":"39","author":"Bebear","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jac\/41.2.179","article-title":"Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis","volume":"41","author":"Doucet-Populaire","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/AAC.00779-07","article-title":"Acute Respiratory Diseases Study, G., Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia","volume":"52","author":"Morozumi","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2022.114252_b0145","series-title":"Macrolide Antibiotics: Chemistr, Biology, and Practice","first-page":"363","article-title":"Antimicrobial Macrolides in Clinical Practice","author":"Alvarez-Elcoro","year":"2003"},{"issue":"suppl A","key":"10.1016\/j.addr.2022.114252_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"issue":"suppl A","key":"10.1016\/j.addr.2022.114252_b0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/25.suppl_A.83","article-title":"Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo","volume":"25","author":"Retsema","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0732-8893(92)90055-X","article-title":"Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview","volume":"15","author":"Hardy","year":"1992","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.addr.2022.114252_b0165","doi-asserted-by":"crossref","unstructured":"P. Kurath, P.H. Jones, R.S. Egan, T.J. Perun, Acid degradation of erythromycin A and erythromycin B, Experientia 27 (4) (1971) 362.","DOI":"10.1007\/BF02137246"},{"issue":"11","key":"10.1016\/j.addr.2022.114252_b0170","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1021\/jm00394a001","article-title":"Macrolides with gastrointestinal motor stimulating activity","volume":"30","author":"Omura","year":"1987","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0090-9556(25)08537-X","article-title":"Metabolism and disposition of clarithromycin in man","volume":"18","author":"Ferrero","year":"1990","journal-title":"Drug Metab. Dispos."},{"issue":"suppl B","key":"10.1016\/j.addr.2022.114252_b0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/20.suppl_B.81","article-title":"Comparative pharmacokinetics of macrolides","volume":"20","author":"Nilsen","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1988.tb05738.x","article-title":"Pharmacokinetics of roxithromycin (RU 965)","volume":"28","author":"Lassman","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2022.114252_b0190","doi-asserted-by":"crossref","unstructured":"A. Markham, D. Faulds, Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use, Drugs 48 (2) (1994) 297\u2013326.","DOI":"10.2165\/00003495-199448020-00011"},{"issue":"7","key":"10.1016\/j.addr.2022.114252_b0195","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/AAC.31.7.1051","article-title":"Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing","volume":"31","author":"Wise","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"suppl B","key":"10.1016\/j.addr.2022.114252_b0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/20.suppl_B.31","article-title":"Factors affecting the in-vitro activity of roxithromycin","volume":"20","author":"Andrews","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0205","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jac\/26.4.503","article-title":"Uptake of clarithromycin by rat lung cells","volume":"26","author":"Kohno","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0210","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/22.6.923","article-title":"An in-vitro evaluation of the cellular uptake and infraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent","volume":"22","author":"Anderson","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0924-8579(01)00430-7","article-title":"Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes","volume":"18","author":"Hand","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0220","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/BF01975835","article-title":"Phagocyte uptake and transport of azithromycin","volume":"10","author":"McDonald","year":"1991","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"7","key":"10.1016\/j.addr.2022.114252_b0225","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.48.1482","article-title":"Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection","volume":"48","author":"Yanagihara","year":"2009","journal-title":"Intern. Med."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00044011-199815020-00009","article-title":"Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers","volume":"15","author":"Ballow","year":"1998","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.addr.2022.114252_b0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","article-title":"Pharmacokinetics of azithromycin in patients with impaired hepatic function","volume":"31 Suppl E","author":"Mazzei","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00003088-198916040-00001","article-title":"Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I)","volume":"16","author":"Periti","year":"1989","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0245","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0250","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1378\/chest.106.4.1116","article-title":"Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis","volume":"106","author":"Oda","year":"1994","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0255","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dkf008","article-title":"Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors","volume":"49","author":"Kikuchi","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0260","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/38.1.81","article-title":"Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro","volume":"38","author":"Abdelghaffar","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/02770909509089507","article-title":"The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma","volume":"32","author":"Kamoi","year":"1995","journal-title":"J. Asthma"},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0270","doi-asserted-by":"crossref","first-page":"e00058","DOI":"10.1002\/prp2.58","article-title":"Azithromycin inhibits nuclear factor- \u03baB activation during lung inflammation: an in vivo imaging study","volume":"2","author":"Stellari","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0275","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.addr.2022.114252_b0280","first-page":"ji1801228","article-title":"Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-\u03baB Signaling Pathways","author":"Haydar","year":"2019","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0285","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1128\/AAC.01142-06","article-title":"Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells","volume":"51","author":"Cigana","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0290","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/j.1476-5381.2011.01576.x","article-title":"Azithromycin distinctively modulates classical activation of human monocytes in vitro","volume":"165","author":"Vrancic","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.addr.2022.114252_b0295","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1167\/iovs.09-4992","article-title":"Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells","volume":"51","author":"Li","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-017-0608-8","article-title":"Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation","volume":"18","author":"Lendermon","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2022.114252_b0305","doi-asserted-by":"crossref","first-page":"12016","DOI":"10.1038\/srep12016","article-title":"Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation","volume":"5","author":"Gualdoni","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0310","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.phrs.2012.06.011","article-title":"Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells","volume":"66","author":"Banjanac","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0315","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0320","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","article-title":"Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells","volume":"42","author":"Moriya","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/09273940903359725","article-title":"Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity","volume":"18","author":"Cheung","year":"2010","journal-title":"Ocul Immunol. Inflamm."},{"issue":"11","key":"10.1016\/j.addr.2022.114252_b0330","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1902\/jop.2011.100721","article-title":"Azithromycin may inhibit interleukin-8 through suppression of Rac1 and a nuclear factor-kappa B pathway in KB cells stimulated with lipopolysaccharide","volume":"82","author":"Matsumura","year":"2011","journal-title":"J. Periodontol."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2249.2011.04480.x","article-title":"The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells","volume":"166","author":"Iwamoto","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.addr.2022.114252_b0340","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, Mechanisms, and Significance of Macrophage Plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu. Rev. Pathol."},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0345","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.addr.2022.114252_b0350","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2022.114252_b0355","doi-asserted-by":"crossref","unstructured":"B.S. Murphy, H.M. Bush, V. Sundareshan, C. Davis, J. Hagadone, T.J. Cory, H. Hoy, D. Hayes, Jr., M.I. Anstead, D.J. Feola, Characterization of macrophage activation states in patients with cystic fibrosis, J. Cyst. Fibros 9 (5) (2010) 314\u2013322.","DOI":"10.1016\/j.jcf.2010.04.006"},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0360","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1258\/002367702320162405","article-title":"Murine models of chronic Pseudomonas aeruginosa lung infection","volume":"36","author":"van Heeckeren","year":"2002","journal-title":"Lab. Anim."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0365","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1128\/AAC.01424-09","article-title":"Azithromycin Alters Macrophage Phenotype and Pulmonary Compartmentalization during Lung Infection with Pseudomonas","volume":"54","author":"Feola","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9338","key":"10.1016\/j.addr.2022.114252_b0370","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.addr.2022.114252_b0375","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"3rd; Macrolide Study, G., Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0380","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"issue":"Suppl 40","key":"10.1016\/j.addr.2022.114252_b0385","first-page":"S39","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.addr.2022.114252_b0390","doi-asserted-by":"crossref","first-page":"3743048","DOI":"10.1155\/2017\/3743048","article-title":"Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy as a Target","volume":"2017","author":"Gao","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0395","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1165\/rcmb.2012-0492TR","article-title":"The neutrophil in chronic obstructive pulmonary disease","volume":"48","author":"Hoenderdos","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122666","article-title":"Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) Release","volume":"18","author":"Bystrzycka","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0405","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200601-071OC","article-title":"Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome","volume":"174","author":"Verleden","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0410","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culic","year":"2002","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0415","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09629350410001688495","article-title":"Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease","volume":"13","author":"Pukhalsky","year":"2004","journal-title":"Mediators Inflamm."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0420","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/jac\/dki251","article-title":"Differential effects of three antibiotics on T helper cell cytokine expression","volume":"56","author":"Williams","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/resp.12415","article-title":"Increased CD8 T-cell granzyme B in COPD is suppressed by treatment with low-dose azithromycin","volume":"20","author":"Hodge","year":"2015","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0430","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.healun.2012.12.016","article-title":"Involvement of interleukin-17 during lymphocytic bronchiolitis in lung transplant patients","volume":"32","author":"Verleden","year":"2013","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.addr.2022.114252_b0435","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1038\/srep07438","article-title":"Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity","volume":"4","author":"Ratzinger","year":"2014","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.addr.2022.114252_b0440","doi-asserted-by":"crossref","first-page":"e0200474","DOI":"10.1371\/journal.pone.0200474","article-title":"Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease","volume":"13","author":"Al-Darraji","year":"2018","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0445","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1084\/jem.20070885","article-title":"The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions","volume":"204","author":"Nahrendorf","year":"2007","journal-title":"J. Exp. Med."},{"issue":"7407","key":"10.1016\/j.addr.2022.114252_b0450","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature11260","article-title":"Myocardial infarction accelerates atherosclerosis","volume":"487","author":"Dutta","year":"2012","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.addr.2022.114252_b0455","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacc.2009.08.089","article-title":"Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis","volume":"55","author":"Panizzi","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0460","first-page":"117","article-title":"Role of innate and adaptive immune mechanisms in cardiac injury and repair","volume":"15","author":"Epelman","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2022.114252_b0465","first-page":"1","article-title":"Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury","author":"Zhang","year":"2015","journal-title":"J. Neuroinflam."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0470","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1038\/srep40144","article-title":"Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment","volume":"7","author":"Gensel","year":"2017","journal-title":"Sci. Rep."},{"issue":"Pt 1","key":"10.1016\/j.addr.2022.114252_b0475","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2015.10.012","article-title":"Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype","volume":"275","author":"Amantea","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.addr.2022.114252_b0480","first-page":"911","article-title":"Post-ischemic treatment with azithromycin protects ganglion cells against retinal ischemia\/reperfusion injury in the rat","volume":"23","author":"Varano","year":"2017","journal-title":"Mol Vis"},{"issue":"3A","key":"10.1016\/j.addr.2022.114252_b0485","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/0002-9343(91)90401-I","article-title":"Clinical toleration and safety of azithromycin","volume":"91","author":"Hopkins","year":"1991","journal-title":"Am. J. Med."},{"issue":"7 Pt 1","key":"10.1016\/j.addr.2022.114252_b0490","doi-asserted-by":"crossref","first-page":"636","DOI":"10.7326\/0003-4819-119-7_Part_1-199310010-00027","article-title":"Azithromycin-induced acute interstitial nephritis","volume":"119","author":"Mansoor","year":"1993","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ijpp.12670","article-title":"Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association","volume":"29","author":"Alsowaida","year":"2021","journal-title":"Int. J. Pharm. Pract."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0500","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2146\/ajhp080687","article-title":"Azithromycin-induced liver injury","volume":"67","author":"Lockwood","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.addr.2022.114252_b0505","doi-asserted-by":"crossref","unstructured":"B.A. Brown, R.J. Wallace, Jr., D.E. Griffith, W. Girard, Clarithromycin-induced hepatotoxicity, Clin. Infect. Dis. 20 (4) (1995) 1073\u20131074.","DOI":"10.1093\/clinids\/20.4.1073"},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0510","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0732-8893(93)90112-K","article-title":"Drug intolerance to high-dose clarithromycin among elderly patients","volume":"16","author":"Wallace","year":"1993","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0515","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025395","article-title":"Resistance to macrolide antibiotics in public health pathogens","volume":"6","author":"Fyfe","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jinf.2007.04.006","article-title":"Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001\u20132004","volume":"55","author":"Felmingham","year":"2007","journal-title":"J. Infect."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0525","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.burns.2011.09.004","article-title":"A high prevalence of mupirocin and macrolide resistance determinant among Staphylococcus aureus strains isolated from burnt patients","volume":"38","author":"Shahsavan","year":"2012","journal-title":"Burns"},{"issue":"8","key":"10.1016\/j.addr.2022.114252_b0530","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1128\/AAC.00663-13","article-title":"Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0535","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"50","key":"10.1016\/j.addr.2022.114252_b0540","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020","volume":"69","author":"St Cyr","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"11","key":"10.1016\/j.addr.2022.114252_b0545","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1099\/jmm.0.000172","article-title":"Antibiotic susceptibility and molecular mechanisms of macrolide resistance in streptococci isolated from adult cystic fibrosis patients","volume":"64","author":"Thornton","year":"2015","journal-title":"J. Med. Microbiol."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0550","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/mdr.2014.0276","article-title":"Characterization of staphylococcus aureus strains isolated from Czech Cystic fibrosis patients: high rate of ribosomal mutation conferring resistance to MLS(B) antibiotics as a result of long-term and low-dose azithromycin treatment","volume":"21","author":"Tkadlec","year":"2015","journal-title":"Microb. Drug Resist."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0555","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1513\/AnnalsATS.201801-012OC","article-title":"Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens","volume":"15","author":"Cogen","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"20","key":"10.1016\/j.addr.2022.114252_b0560","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2002606","article-title":"Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution","volume":"383","author":"Doan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0565","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1378\/chest.115.4.983","article-title":"The effects of erythromycin on the electrocardiogram","volume":"115","author":"Mishra","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.addr.2022.114252_b0570","doi-asserted-by":"crossref","unstructured":"S.J. Stanat, C.G. Carlton, W.J. Crumb, Jr., K.C. Agrawal, C.W. Clarkson, Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel, Mol. Cell Biochem. 254 (1-2) (2003) 1\u20137.","DOI":"10.1023\/A:1027309703313"},{"issue":"8","key":"10.1016\/j.addr.2022.114252_b0575","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjp.0706900","article-title":"No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block","volume":"149","author":"Thomsen","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"5\u20136","key":"10.1016\/j.addr.2022.114252_b0580","first-page":"211","article-title":"Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture","volume":"16","author":"Carlier","year":"1994","journal-title":"Int. J. Tissue React."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0585","first-page":"30","article-title":"Azithromycin-induced QT prolongation in elderly patient","volume":"77","author":"Russo","year":"2006","journal-title":"Acta Biomed"},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0590","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10840-007-9124-y","article-title":"Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors","volume":"18","author":"Kezerashvili","year":"2007","journal-title":"J. Interv. Card Electrophysiol."},{"issue":"1185","key":"10.1016\/j.addr.2022.114252_b0595","first-page":"U666","article-title":"A case of QT-interval prolongation precipitated by azithromycin","volume":"116","author":"Matsunaga","year":"2003","journal-title":"N. Z. Med. J."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0600","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1046\/j.1460-9592.2001.01572.x","article-title":"QT prolongation associated with azithromycin\/amiodarone combination","volume":"24","author":"Samarendra","year":"2001","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0605","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/j.1540-8159.2007.00912.x","article-title":"Azithromycin-induced torsade de pointes","volume":"30","author":"Huang","year":"2007","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0610","first-page":"613","article-title":"The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases","volume":"5","author":"Hui","year":"2013","journal-title":"J. Thorac Dis."},{"issue":"16","key":"10.1016\/j.addr.2022.114252_b0615","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2169\/internalmedicine.50.4727","article-title":"Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases","volume":"50","author":"Li","year":"2011","journal-title":"Intern. Med."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0620","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.healun.2004.08.006","article-title":"Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients","volume":"24","author":"Shitrit","year":"2005","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.addr.2022.114252_b0625","doi-asserted-by":"crossref","unstructured":"R.K. Albert, J. Connett, W.C. Bailey, R. Casaburi, J.A. Cooper, Jr., G.J. Criner, J.L. Curtis, M.T. Dransfield, M.K. Han, S.C. Lazarus, B. Make, N. Marchetti, F.J. Martinez, N.E. Madinger, C. McEvoy, D.E. Niewoehner, J. Porsasz, C.S. Price, J. Reilly, P.D. Scanlon, F.C. Sciurba, S.M. Scharf, G.R. Washko, P.G. Woodruff, N.R. Anthonisen, Network, C. C. R., Azithromycin for prevention of exacerbations of COPD, N Engl. J. Med. 365 (8) (2011) 689\u2013698.","DOI":"10.1056\/NEJMoa1104623"},{"key":"10.1016\/j.addr.2022.114252_b0630","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/COPD.S23655","article-title":"Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations","volume":"6","author":"Pomares","year":"2011","journal-title":"Int. J. Chron Obstruct. Pulmon Dis."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1164\/rccm.201602-0223ED","article-title":"IFN Deficiency in Asthma Attacks. Is Restoring Toll-like Receptor-7 Expression a New Treatment Approach in Severe Asthma?","volume":"194","author":"Johnston","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10095","key":"10.1016\/j.addr.2022.114252_b0640","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2022.114252_b0645","doi-asserted-by":"crossref","unstructured":"D.L. Hahn, M. Grasmick, S. Hetzel, S. Yale, Group, A. S., Azithromycin for bronchial asthma in adults: an effectiveness trial, J. Am. Board Fam. Med. 25 (4) (2012) 442\u2013459.","DOI":"10.3122\/jabfm.2012.04.110309"},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0650","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0655","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/jcmm.13919","article-title":"The efficacy and safety of azithromycin in asthma: A systematic review","volume":"23","author":"Tian","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0660","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","article-title":"Ion Channel Modulators in Cystic Fibrosis","volume":"154","author":"Gentzsch","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.addr.2022.114252_b0665","unstructured":"L. Saiman, M. Anstead, N. Mayer-Hamblett, L.C. Lands, M. Kloster, J. Hocevar-Trnka, C.H. Goss, L.M. Rose, J.L. Burns, B.C. Marshall, F. Ratjen, Group, A. Z. A. S., Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial, JAMA 303 (17) (2010) 1707\u20131715."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0670","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0675","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","article-title":"Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis","volume":"201","author":"Nichols","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0680","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.addr.2022.114252_b0685","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2022.114252_b0690","unstructured":"US National Library of Medicine, ClinicalTrials.gov. Accessed Dec 21, 2021."},{"key":"10.1016\/j.addr.2022.114252_b0695","doi-asserted-by":"crossref","unstructured":"S.L. Johnston, M. Szigeti, M. Cross, C. Brightling, R. Chaudhuri, T. Harrison, A. Mansur, L. Robison, Z. Sattar, D. Jackson, P. Mallia, E. Wong, C. Corrigan, B. Higgins, P. Ind, D. Singh, N.C. Thomson, D. Ashby, A. Chauhan, Team, A. T., Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial, JAMA Intern. Med. 176 (11) (2016) 1630\u20131637.","DOI":"10.1001\/jamainternmed.2016.5664"},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0700","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1183\/09031936.00093913","article-title":"Randomised controlled trial of azithromycin in smokers with asthma","volume":"42","author":"Cameron","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2022.114252_b0705","doi-asserted-by":"crossref","unstructured":"L.B. Bacharier, T.W. Guilbert, D.T. Mauger, S. Boehmer, A. Beigelman, A.M. Fitzpatrick, D.J. Jackson, S.N. Baxi, M. Benson, C.D. Burnham, M. Cabana, M. Castro, J.F. Chmiel, R. Covar, M. Daines, J.M. Gaffin, D.A. Gentile, F. Holguin, E. Israel, H.W. Kelly, S.C. Lazarus, R.F. Lemanske, Jr. N. Ly, K. Meade, W. Morgan, J. Moy, T. Olin, S.P. Peters, W. Phipatanakul, J.A. Pongracic, H.H. Raissy, K. Ross, W.J. Sheehan, C. Sorkness, S.J. Szefler, W.G. Teague, S. Thyne, F.D. Martinez, Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial, J. Am. Med. Assoc. 314 (19) (2015) 2034\u20132044.","DOI":"10.1001\/jama.2015.13896"},{"key":"10.1016\/j.addr.2022.114252_b0710","doi-asserted-by":"crossref","unstructured":"E.R. Sutherland, T.S. King, N. Icitovic, B.T. Ameredes, E. Bleecker, H.A. Boushey, W.J. Calhoun, M. Castro, R.M. Cherniack, V.M. Chinchilli, T.J. Craig, L. Denlinger, E.A. DiMango, J.V. Fahy, E. Israel, N. Jarjour, M. Kraft, S.C. Lazarus, R.F. Lemanske, Jr., S.P. Peters, J. Ramsdell, C.A. Sorkness, S.J. Szefler, M.J. Walter, S.I. Wasserman, M.E. Wechsler, H.W. Chu, R.J. Martin, National Heart, L., Blood Institute's Asthma Clinical Research, N., A trial of clarithromycin for the treatment of suboptimally controlled asthma, J. Allergy Clin. Immunol. 126 (4) (2010) 747\u2013753.","DOI":"10.1016\/j.jaci.2010.07.024"},{"key":"10.1016\/j.addr.2022.114252_b0715","doi-asserted-by":"crossref","unstructured":"K. Vermeersch, A. Belmans, K. Bogaerts, I. Gyselinck, N. Cardinaels, M. Gabrovska, J. Aumann, I.K. Demedts, J.L. Corhay, E. Marchand, H. Slabbynck, C. Haenebalcke, S. Vermeersch, G.M. Verleden, T. Troosters, V. Ninane, G.G. Brusselle, W. Janssens, investigators, B. t., Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial, Respir. Res. 20 (1) (2019) 237.","DOI":"10.1186\/s12931-019-1208-6"},{"issue":"8","key":"10.1016\/j.addr.2022.114252_b0720","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/resp.12375","article-title":"Efficacy of azithromycin in the treatment of bronchiectasis","volume":"19","author":"Lourdesamy","year":"2014","journal-title":"Respiraology"},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0725","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0730","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ajt.13417","article-title":"Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial","volume":"16","author":"Ruttens","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0735","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000509462","article-title":"Use of azithromycin for the prevention of lung injury in mechanically ventilated preterm neonates: A randomized controlled trial","volume":"117","author":"Nunes","year":"2020","journal-title":"Neonatology"},{"issue":"10256","key":"10.1016\/j.addr.2022.114252_b0740","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0745","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S2213-2600(21)00263-0","article-title":"Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial","volume":"9","author":"Hinks","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0750","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.2021.11517","article-title":"Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"326","author":"Oldenburg","year":"2021","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0755","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/gutjnl-2017-315199","article-title":"Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial","volume":"68","author":"Levine","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.addr.2022.114252_b0760","doi-asserted-by":"crossref","unstructured":"N. Mayer-Hamblett, G. Retsch-Bogart, M. Kloster, F. Accurso, M. Rosenfeld, G. Albers, P. Black, P. Brown, A. Cairns, S.D. Davis, G.R. Graff, G.S. Kerby, D. Orenstein, R. Buckingham, B.W. Ramsey, Group, O. S., Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial, Am. J. Respir Crit. Care Med. 198 (9) (2018) 1177\u20131187.","DOI":"10.1164\/rccm.201808-1462LE"},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0765","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ICL.0b013e31823ff229","article-title":"Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye","volume":"38","author":"Nichols","year":"2012","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.addr.2022.114252_b0770","doi-asserted-by":"crossref","unstructured":"R.A. Ferrand, G. McHugh, A.M. Rehman, H. Mujuru, V. Simms, E.D. Majonga, M.P. Nicol, T. Flaegstad, T.J. Gutteberg, C. Gonzalez-Martinez, E.L. Corbett, S.L. Rowland-Jones, K. Kranzer, H.A. Weiss, J.O. Odland, Group, B. T., Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease: The BREATHE Randomized Clinical Trial, JAMA Netw. Open 2020, 3 (12), e2028484.","DOI":"10.1001\/jamanetworkopen.2020.28484"},{"key":"10.1016\/j.addr.2022.114252_b0775","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2017.05.008","article-title":"Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial","volume":"144","author":"Lee","year":"2017","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0780","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healun.2018.12.006","article-title":"Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial","volume":"38","author":"Van Herck","year":"2019","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.addr.2022.114252_b0785","doi-asserted-by":"crossref","unstructured":"C.M. Jespersen, B. Als-Nielsen, M. Damgaard, J.F. Hansen, S. Hansen, O.H. Helo, P. Hildebrandt, J. Hilden, G.B. Jensen, J. Kastrup, H.J. Kolmos, E. Kjoller, I. Lind, H. Nielsen, L. Petersen, C. Gluud, C.T. Group, Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial, Brit. Med. J. 332 (7532) (2006) 22\u201327.","DOI":"10.1136\/bmj.38666.653600.55"},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0790","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.02974-15","article-title":"Clarithromycin leads to long-term survival and cost benefit in ventilator-associated pneumonia and sepsis","volume":"60","author":"Tsaganos","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0795","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3810\/pgm.2011.09.2478","article-title":"Treatment of rheumatoid arthritis with roxithromycin: a randomized trial","volume":"123","author":"Ogrendik","year":"2011","journal-title":"Postgrad. Med."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0800","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.addr.2022.114252_b0805","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1365-2036.2008.03661.x","article-title":"Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease","volume":"27","author":"Leiper","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Supplement_6","key":"10.1016\/j.addr.2022.114252_b0810","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis","volume":"14","author":"Moller","year":"2017","journal-title":"Ann. Am. Thorac Soc."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0815","first-page":"50","article-title":"NF-kappaB activation in sarcoidosis","volume":"18","author":"Drent","year":"2001","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0820","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1165\/rcmb.2018-0298ED","article-title":"Macrophage Polarization in Sarcoidosis: An Unexpected Accomplice?","volume":"60","author":"Standiford","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"9030","key":"10.1016\/j.addr.2022.114252_b0825","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(05)65205-1","article-title":"Mycobacteria and sarcoidosis","volume":"348","author":"Mitchell","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0830","first-page":"201","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis","volume":"30","author":"Drake","year":"2013","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0835","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"Drake","year":"2021","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0840","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study","volume":"149","author":"Drake","year":"2013","journal-title":"JAMA Dermatol."},{"issue":"23","key":"10.1016\/j.addr.2022.114252_b0845","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2022.114252_b0850","unstructured":"P.G. Richardson, A. Oriol, M. Beksac, A.M. Liberati, M. Galli, F. Schjesvold, J. Lindsay, K. Weisel, D. White, T. Facon, J. San Miguel, K. Sunami, P. O'Gorman, P. Sonneveld, P. Robak, S. Semochkin, S. Schey, X. Yu, T. Doerr, A. Bensmaine, T. Biyukov, T. Peluso, M. Zaki, K. Anderson, M. Dimopoulos, investigators, O. t., Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 20 (6) (2019) 781\u2013794."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0855","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0860","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1081-1206(10)62264-8","article-title":"Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study","volume":"87","author":"Spahn","year":"2001","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0865","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2249.1996.46752.x","article-title":"Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells","volume":"104","author":"Matsuoka","year":"1996","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0870","first-page":"815","article-title":"Clarithromycin attenuates autophagy in myeloma cells","volume":"37","author":"Nakamura","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0875","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/bloodadvances.2018028027","article-title":"Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma","volume":"3","author":"Mark","year":"2019","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b0880","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jaci.2014.10.001","article-title":"Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis","volume":"135","author":"Beigelman","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2022.114252_b0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100798","article-title":"The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population","volume":"22","author":"Srinivasan","year":"2021","journal-title":"Contemp Clin. Trials Commun."},{"key":"10.1016\/j.addr.2022.114252_b0890","doi-asserted-by":"crossref","unstructured":"M.C. Kneyber, J.B. van Woensel, E. Uijtendaal, C.S. Uiterwaal, J.L. Kimpen; Dutch Antibiotics in, R. S. V. T. R. G., Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial, Pediatr Pulmonol 43 (2) (2008) 142\u2013149.","DOI":"10.1002\/ppul.20748"},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0895","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jpeds.2012.05.053","article-title":"Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial","volume":"161","author":"Pinto","year":"2012","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2022.114252_b0900","series-title":"Nanomaterials for Clinical Applications: Case Studies in Nanomedicines","first-page":"159","article-title":"Modulating the immune reponse with liposomal delivery","author":"Nardo","year":"2020"},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0905","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","article-title":"Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties","volume":"65","author":"Touitou","year":"2000","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194179","article-title":"Niosomes, an alternative for liposomal delivery","volume":"13","author":"Bartelds","year":"2018","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0915","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02652049109071486","article-title":"Liposomes as carriers of macrolides: preferential association of erythromycin A and azithromycin with liposomes of phosphatidylglycerol containing unsaturated fatty acid(s)","volume":"8","author":"Stuhne-Sekalec","year":"1991","journal-title":"J. Microencapsul."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b0920","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1128\/AAC.39.9.2104","article-title":"Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection","volume":"39","author":"Oh","year":"1995","journal-title":"Antimicrob. Agent Chemother."},{"key":"10.1016\/j.addr.2022.114252_b0925","doi-asserted-by":"crossref","unstructured":"G. Gregoriadis, Y. Perrie, Liposomes, in: Encylcopedia of Life Sciences, John Wiley & Sons, Ltd., Chichester, 2010.","DOI":"10.1002\/9780470015902.a0002656.pub2"},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0930","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000211363","article-title":"Optimization of topical erythromycin formulations by ion pairing","volume":"8","author":"Matschiner","year":"1995","journal-title":"Skin Pharmacol."},{"issue":"11","key":"10.1016\/j.addr.2022.114252_b0935","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1021\/acs.molpharmaceut.8b00516","article-title":"Encapsulation of azithromycin ion pair in liposome for enhancing ocular delivery and therapeutic efficacy on dry eye","volume":"15","author":"Ren","year":"2018","journal-title":"Mol. Pharmaceut."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b0940","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/mp900243b","article-title":"Cancer therapies utilizing the camptothecins: a review of the in vivo literature","volume":"7","author":"Venditto","year":"2010","journal-title":"Mol. Pharmaceut."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0945","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2012.09.038","article-title":"Cancer nanomedicines: so many papers and so few drugs!","volume":"65","author":"Venditto","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114252_b0950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/OED.S7791","article-title":"Review of Azithromycin Ophthalmic 1% Solution (AzaSite((R))) for the Treatment of Ocular Infections","volume":"4","author":"Opitz","year":"2012","journal-title":"Ophthalmol. Eye Dis."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0955","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.nano.2010.10.008","article-title":"Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation","volume":"7","author":"Bosnjakovic","year":"2011","journal-title":"Nanomed."},{"issue":"7","key":"10.1016\/j.addr.2022.114252_b0960","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.3390\/molecules18078607","article-title":"The effect of PAMAM dendrimers on the antibacterial activity of antibiotics with different water solubility","volume":"18","author":"Winnicka","year":"2013","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b0965","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.nano.2011.04.008","article-title":"PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections","volume":"7","author":"Mishra","year":"2011","journal-title":"Nanomed."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b0970","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpb.2013.12.018","article-title":"Ionic polymeric micelles based on chitosan and fatty acids and intended for wound healing. Comparison of linoleic and oleic acid","volume":"87","author":"Bonferoni","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b0975","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1021\/js960040u","article-title":"Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study","volume":"85","author":"Jayaraman","year":"1996","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.addr.2022.114252_b0980","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2018.10.024","article-title":"Azithromycin-loaded liposomes for enhanced topical treatment of methicillin-resistant Staphyloccocus aureus (MRSA) infections","volume":"553","author":"Rukavina","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114252_b0985","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.2147\/IJN.S211691","article-title":"Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections","volume":"14","author":"Vanic","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2022.114252_b0990","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejpb.2017.01.006","article-title":"Topical delivery of roxithromycin solid-state forms entrapped in vesicles","volume":"114","author":"Csongradi","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b0995","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2174\/1567201054367931","article-title":"Erythromycin ethosomal systems: physicochemical characterization and enhanced antibacterial activity","volume":"2","author":"Godin","year":"2005","journal-title":"Curr. Drug Deliv."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b1000","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jac\/dki125","article-title":"A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study","volume":"55","author":"Godin","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2022.114252_b1005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biomaterials.2017.07.009","article-title":"Combined photodynamic and antibiotic therapy for skin disorder via lipase-sensitive liposomes with enhanced antimicrobial performance","volume":"141","author":"Jeong","year":"2017","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b1010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0781.2008.00376.x","article-title":"Role of photodynamic therapy in psoriasis: a brief review","volume":"24","author":"Tandon","year":"2008","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdermsci.2016.07.007","article-title":"Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice","volume":"84","author":"Huang","year":"2016","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b1020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1684\/ejd.2010.0930","article-title":"Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial","volume":"20","author":"Saxena","year":"2010","journal-title":"Eur. J. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2014.06.019","article-title":"Polymeric nanoparticles-embedded organogel for roxithromycin delivery to hair follicles","volume":"88","author":"Glowka","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b1030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ijpharm.2015.09.068","article-title":"Roxithromycin-loaded lipid nanoparticles for follicular targeting","volume":"495","author":"Wosicka-Frackowiak","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b1035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/dth.12357","article-title":"Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis","volume":"29","author":"Rajabi","year":"2016","journal-title":"Dermatol. Ther."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b1040","first-page":"383","article-title":"Effect of adjunctive topical liposomal azithromycin on systemic azithromycin on old world cutaneous leishmaniasis: a pilot clinical study","volume":"20","author":"Abtahi-Naeini","year":"2021","journal-title":"Iran J. Pharm. Res."},{"key":"10.1016\/j.addr.2022.114252_b1045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00044011-200222060-00007","article-title":"Comparative tolerability of intravenous erythromycin and clarithromycin in hospitalized patients with community-aquired pneumonia","volume":"22","author":"de Celis","year":"2002","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.addr.2022.114252_b1050","doi-asserted-by":"crossref","DOI":"10.2165\/00044011-200121080-00001","article-title":"Comparative tolerability of intravenous azithromycin, clarithromycin and erythromycin in healthy volunteers","volume":"21","author":"Zimmermann","year":"2001","journal-title":"Clin. Drug Invest."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b1055","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/BF02980275","article-title":"Formulation and evaluation of less-painful clarithromycin lipid microspheres","volume":"30","author":"LingHao","year":"2007","journal-title":"Arch Pharm. Res."},{"key":"10.1016\/j.addr.2022.114252_b1060","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.colsurfb.2018.08.038","article-title":"Capacity of cholesteryl hemisuccinate in ion pair\/phospholipid complex to improve drug-loading, stability and antibacterial activity of clarithromycin intravenous lipid microsphere","volume":"172","author":"Luo","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1\u20132","key":"10.1016\/j.addr.2022.114252_b1065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijpharm.2013.01.023","article-title":"Clarithromycin-loaded liposomes offering high drug loading and less irritation","volume":"443","author":"Liu","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2022.114252_b1070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/10717544.2013.834415","article-title":"Characteristics and evaluation of an injectable clarithromycin lipid-based complex in vitro and in vivo","volume":"20","author":"Ma","year":"2013","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b1075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/17425247.2016.1123247","article-title":"Clarithromycin ion pair in a liposomal membrane to improve its stability and reduce its irritation caused by intravenous administration","volume":"13","author":"Geng","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.addr.2022.114252_b1080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2007.12.046","article-title":"Optimization of tocol emulsions for the intravenous delivery of clarithromycin","volume":"356","author":"Li","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.addr.2022.114252_b1085","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s11095-014-1382-7","article-title":"Azithromycin cationic non-lecithoid nano\/microparticles improve bioavailability and targeting efficiency","volume":"31","author":"Zhong","year":"2014","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b1090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/10717544.2014.880756","article-title":"Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcus aureus infection","volume":"22","author":"Li","year":"2015","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b1095","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11095-015-1825-9","article-title":"Multi-functional liposomes enhancing target and antibacterial immunity for antimicrobial and anti-biofilm against methicillin-resistant Staphylococcus aureus","volume":"33","author":"Meng","year":"2016","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12951-021-00845-0","article-title":"On-demand pH-sensitive surface charge-switchable polymeric micelles for targeting Pseudomonas aeruginosa biofilms development","volume":"19","author":"Chen","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b1105","first-page":"375","article-title":"Clarithromycin targeting to lung: optimization of the size, morphology and release characteristics of albumin microspheres","volume":"57","author":"Ozkan","year":"2000","journal-title":"Acta Pol. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40199-016-0153-x","article-title":"High azithromycin concentration in lungs by way of bovine serum albumin microspheres as targeted drug delivery: lung targeting efficiency in albino mice","volume":"24","author":"Ramaiah","year":"2016","journal-title":"Daru"},{"issue":"5","key":"10.1016\/j.addr.2022.114252_b1115","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1021\/acsnano.0c00269","article-title":"Size and charge adaptive clustered nanoparticles targeting the biofilm microenvironment for chronic lung infection management","volume":"14","author":"Gao","year":"2020","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1120","first-page":"3","article-title":"Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy","volume":"1","author":"Friedlaender","year":"2007","journal-title":"Clin. Ophthalmol."},{"issue":"4","key":"10.1016\/j.addr.2022.114252_b1125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040523","article-title":"Clarithromycin solid lipid nanoparticles for topical ocular therapy: optimization, evaluation and in vivo studies","volume":"13","author":"Nair","year":"2021","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.addr.2022.114252_b1130","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/j.xphs.2021.04.020","article-title":"Novel chitosan-coated niosomal formulation for improved management of bacterial conjunctivitis: a highly permeable and efficient ocular nanocarrier for Azithromycin","volume":"110","author":"Eid","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114252_b1135","doi-asserted-by":"crossref","first-page":"7861","DOI":"10.2147\/IJN.S269004","article-title":"Clarithromycin-loaded ocular chitosan nanoparticle: formulation, optimization, characterization, ocular irritation, and antimicrobial activity","volume":"15","author":"Bin-Jumah","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2022.114252_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120900","article-title":"A non-invasive nanoparticle-based sustained dual-drug delivery system as an eyedrop for endophthalmitis","volume":"606","author":"Mahaling","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114252_b1145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2019.02.039","article-title":"Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm","volume":"300","author":"Li","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbrc.2017.09.060","article-title":"Erythromycin encapsulation in nanoemulsion-based delivery systems for treatment of Helicobacter pylori infection: Protection and synergy","volume":"493","author":"Tran","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b1155","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1080\/10717544.2016.1196768","article-title":"Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin","volume":"23","author":"Ullah","year":"2016","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.addr.2022.114252_b1160","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/03639045.2017.1291667","article-title":"Creatinine-based non-phospholipid vesicular carrier for improved oral bioavailability of Azithromycin","volume":"43","author":"Ullah","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"9","key":"10.1016\/j.addr.2022.114252_b1165","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10611860802295839","article-title":"Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori","volume":"16","author":"Ramteke","year":"2008","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.addr.2022.114252_b1170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/10611860902718649","article-title":"Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori","volume":"17","author":"Ramteke","year":"2009","journal-title":"J. Drug Target."},{"issue":"2","key":"10.1016\/j.addr.2022.114252_b1175","article-title":"Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection","volume":"1","author":"Angsantikul","year":"2018","journal-title":"Adv. Ther. (Weinh)"},{"issue":"1","key":"10.1016\/j.addr.2022.114252_b1180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/acs.molpharmaceut.9b00721","article-title":"Fast biofilm penetration and anti-PAO1 activity of nebulized azithromycin in nanoarchaeosomes","volume":"17","author":"Altube","year":"2020","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.addr.2022.114252_b1185","first-page":"6492953","article-title":"In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin","volume":"2016","author":"Shilakari Asthana","year":"2016","journal-title":"Scientifica (Cairo)"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22001429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22001429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:24:13Z","timestamp":1759209853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22001429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":237,"alternative-id":["S0169409X22001429"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114252","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivering macrolide antibiotics to heal a broken heart \u2013 And other inflammatory conditions","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114252"}}